Latisse is now name brand which expensive.When it become generic it will be cheaper.
The first patent listed with the U.S. Food and Drug Administration (FDA) for Latisse expired in September 2012. However, this patent refers to the use of bimatoprost (the active ingredient in Latisse) to treat glaucoma, so the patent probably applies only to Lumigan, a medication that contains the same active ingredient as Latisse.
The first patent for Latisse that specifically mentions eyelashes is set to expire in January 2022. At this point, January 2022 is the earliest predictable date that a generic version of Latisse may become available.
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 25 Nov 2010 • 1 answer
Posted 1 Dec 2010 • 1 answer
Posted 17 Apr 2013 • 1 answer
Posted 27 Oct 2016 • 1 answer
Posted 17 Jun 2017 • 3 answers